Glucagon-like peptide-1 receptor agonists are increasingly prescribed to reproductive-aged patients, yet pharmacovigilance data on menstrual outcomes remain sparse. Using the FDA Adverse Event Reporting System data through March 2026, we performed disproportionality and Bayesian analyses restricted to female patients aged 12-55 years in a retrospective cohort study. Semaglutide demonstrated the broadest signal profile, with disproportionate reporting of heavy menstrual bleeding, intermenstrual bleeding, menstrual clots, oligomenorrhea, and anovulatory cycles. Tirzepatide generated signals for intermenstrual bleeding and menstrual clots. Liraglutide produced no significant signals. These findings suggest pleiotropic effects on menstrual physiology and may support inclusion of menstrual health in counseling for reproductive-aged patients.

An Ebola virus outbreak in the Democratic Republic of the Congo has been declared a Public Health Emergency of International Concern. In recent years, substantial advances in evidence-based clinical guidelines, vaccines, and therapeutics have been made, leading to improved outcomes. Our understanding regarding pregnancy outcomes has evolved; maternal mortality rates appear lower than previously believed, but vertical transmission and neonatal death rates remain high. Information gaps persist, particularly regarding infection with Bundibugyo ebolavirus, the species responsible for the current outbreak. No licensed therapeutics or vaccines are available, although candidates are promising. Including pregnant individuals in trials is critical to generating evidence on safety and efficacy of therapeutics during pregnancy. Here we provide an update regarding Ebola virus disease and implications for pregnancy.

In the United States and globally, the negative effects of climate change, such as extremes of heat, wildfire smoke, and air pollution, are associated with early pregnancy loss, preterm birth, preeclampsia, hypertensive disorders of pregnancy, and stillbirth. Climate change amplifies existing gender-based disparities, which include elevated risks of infectious diseases, malnutrition, sexual violence, mental health disorders, lack of reproductive control, negative obstetric outcomes, and death, when compared with men. These adverse effects disproportionately affect marginalized groups. With the ongoing and increasing threats of climate change and environmental pollutants on human health, it is imperative that obstetrician-gynecologists (ob-gyns) educate not only themselves but students, other health care professionals, their patients, and communities about the adverse effects these threats have on gynecologic and obstetric health. Institutions should encourage the inclusion of climate change education in medical curricula. Ob-gyns should incorporate environmental health education into all prepregnancy counseling visits, with a focus on identifying any potential harmful exposures and determining what mitigation efforts can be initiated before pregnancy.

Significant disparities in surgical reimbursement by patient sex have been documented for decades, although debate exists regarding their cause, and studies have approached the issue with different methodologies, arriving at seemingly divergent conclusions. In our analysis, we have found that the preponderance of the literature, including the most comprehensive studies, supports a conclusion that there are real payment disparities at the work relative value unit (RVU) level for gynecologic care. Disparities in funding and reimbursement result in differing health care resource allocation and access and ultimately systemic and persistent devaluation of female bodies. We advocate for robust interventions to promote equity rather than a limited approach focused on revising a handful of Current Procedural Terminology codes. Reforms should include broader RVU reassessment, specialty compensation parity, and rigorous yet inclusive comparisons of sex-specific procedures.